10-K: Petros Pharmaceuticals Shifts Focus to OTC Platform Development Amid Financial Challenges

Petros Pharmaceuticals discontinues Stendra sales and pivots towards developing a proprietary OTC technology platform while facing significant financial hurdles and going concern doubts.

Summary

• Petros Pharmaceuticals, Inc. is shifting its focus from commercializing Stendra to developing a proprietary technology platform aimed at facilitating Rx-to-OTC switches for pharmaceutical companies.
• The company has discontinued sales of Stendra to wholesalers and terminated its agreement with Vivus, impacting its revenue streams.
• Petros is facing significant financial challenges, including recurring losses, negative working capital of $10.7 million, and an accumulated deficit of $113.2 million as of December 31, 2024.
• There is substantial doubt about the company's ability to continue as a going concern, requiring additional capital to fund operations.
• The company is pursuing the development of a SaaS and SaMD platform to assist pharmaceutical companies in navigating the Rx-to-OTC switch process.
• Petros defaulted on its Promissory Note with Vivus, leading to the forfeiture of assets and increasing financial obligations.
• The company is exploring various financing strategies, including debt and equity offerings, to address its liquidity concerns.
• Metuchen, a subsidiary of Petros, is undergoing an assignment for the benefit of creditors (ABC), leading to its deconsolidation from the company's financial statements.
• The company's stock price is volatile, and it faces potential delisting from The Nasdaq Capital Market.
• Petros is subject to evolving regulations related to AI technologies, which could impact its business.

Sentiment

Score: 3

Explanation: The document presents a concerning financial situation with a shift in business strategy, raising significant doubts about the company's future prospects.

Positives

• Petros is focusing on the emerging self-care market with its proprietary technology platform.
• The company is leveraging recent FDA rules, such as the ACNU Rule, to expand access to nonprescription pharmaceuticals.
• Petros has an established industry-wide network of prospective companies that may license its technology.
• The company's extensive experience in product distribution remains a key asset.

Negatives

• Petros has discontinued sales of Stendra, impacting its revenue streams.
• The company has incurred significant losses and may continue to experience losses in the future.
• There is substantial doubt about Petros' ability to continue as a going concern.
• The company defaulted on its Promissory Note with Vivus, forfeiting assets and increasing financial obligations.
• Petros has concluded that there are material weaknesses in its internal control over financial reporting.
• The company's stock price is volatile and faces potential delisting from The Nasdaq Capital Market.

Risks

• Petros' ability to continue as a going concern is uncertain, requiring additional capital.
• The company's focus on platform development may adversely impact its operations and financial performance.
• Petros' technology may be viewed as relatively new or untested, which could result in regulatory delays.
• The company may not receive the necessary authorizations to market its platform or any future new products.
• Petros may be subject to potential product liability and other claims.
• The company may be subject to certain federal, state, and foreign fraud and abuse laws.
• Changes in laws could negatively impact Petros' business.
• The regulatory framework for artificial intelligence (AI) technologies is rapidly evolving.

Future Outlook

Petros is focused on developing and licensing its proprietary technology platform for Rx-to-OTC switches, with primary revenue streams intended to stem from licensing fees and customized virtual web-based environments.

Industry Context

The self-care market is valued at $38 billion and is projected to grow, driven by the increase in consumers desire to seek self-managed healthcare options, such as readily available access to prescription medication over-the-counter, which in turn, contributes to a growing demand for safe, accessible and effective OTC solutions for pharmaceutical companies.

Comparison to Industry Standards

• Currently, the Rx-to-OTC industry is driven by individual sponsors, each working independently to transition their products from prescription to OTC.
• In terms of technology-centered switches, such as ACNUs, only a handful of companies are actively developing proprietary software products, including established pharmaceutical companies, such as Astra Zeneca and Sanofi, without clear interest in establishing their own technology platforms for future licensing capabilities and instead remaining focused on their independent product development efforts.
• Several technology firms, such as Idea Evolver, are already providing critical support to sponsors in their ACNU switch platforms.
• To date, there are no FDA-approved ACNU therapeutics that have switched from Rx-to-OTC and therefore no proven conceptor technology platform has been established for FDA-approved commercialization or licensable potential in this area.

Related Party Transactions

• In connection with the Private Placement, in July 2023, we issued to Alto Opportunity Master Fund, SPC Segregated Master Portfolio B (Alto) 1,000 shares of our Series A Preferred Stock and Warrants to purchase up to 444,444 shares of Common Stock, which beneficially owned more than 5% of our voting securities, for aggregate gross proceeds of $1 million.
• On November 28, 2023, the Board approved a payment to JCP III AIV of $125,000 in recognition of various management and advisory services previously provided to the Company by JCP III AIV.
• On February 17, 2025, the Company entered into the Public Offering Purchase Agreement with certain institutional and accredited investors, including Five Narrow Lane LP (Five Narrow), 3i, LP (3i), Iroquois Master Fund Ltd. (IMF), Iroquois Capital Investment Group, LLC (ICIG) and Alto, each of which beneficially own 5% or more of the Companys voting securities.

Stakeholder Impact

• Shareholders may experience dilution due to potential equity offerings.
• Employees may face uncertainty due to the company's financial challenges and strategic shift.
• Customers may be affected by the discontinuation of Stendra and the focus on new OTC products.
• Suppliers and creditors may be impacted by the company's financial difficulties and potential restructuring.

Next Steps

• The company intends to submit a plan to regain compliance with the Bid Price Listing Rule.
• The Company is evaluating various financing strategies to obtain sufficient additional liquidity to meet its operating, debt service and capital requirements for the next twelve months following the date of our consolidated financial statements included in this annual report.

Key Dates

Keywords

Petros Pharmaceuticals, Rx-to-OTC switch, technology platform, financial performance, going concern, Stendra, Vivus, ACNU, SaMD, SaaS